Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2016

01-04-2016 | Review

The role of miRNAs in the pheochromocytomas

Authors: Zheng Li, Xin Yu, Jianxiong Shen

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

Pheochromocytoma (PCC) is a catecholamine-producing and neuroendocrine tumor, which originates from chromaffin cells in adrenal medulla or at extra-adrenal sites. The clinical symptoms of PCC patients were including paroxysmal hypertension and cardiovascular crises. Despite the identification of many molecular-level basics involved in these pathogenesis processes, the 5-year survival of advanced stage PCC is <40 %. The 5-year survival of advanced stage PCC is <40 %. microRNAs (miRNAs) are a class of single-strand, highly conserved, small, non-coding RNAs which inhibit gene expression by binding to the target messenger RNA (mRNA) 3′UTR to induce translational repression or their degradation. Increasing data have shown that the deregulated expression of miRNAs has been implicated in the diagnosis and treatment of tumors including PCC. In this review, we summarized the expressions and roles of miRNAs in PCC and comment on the potential role of miRNAs in improving diagnosis, prognosis, and treatment of PCC.
Literature
1.
Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014;60:1486–99.CrossRefPubMed
2.
3.
Ditkofsky N, Workman C. Pheochromocytoma supporting blood pressure in the setting of cardiogenic shock. Clin Imaging. 2015;39:136–9.CrossRefPubMed
4.
Chen Y, Hodin RA, Pandolfi C, Ruan DT, McKenzie TJ. Hypoglycemia after resection of pheochromocytoma. Surgery. 2014;156:1404–8. discussion 1408–1409.CrossRefPubMed
5.
Kim HJ, Lee JI, Cho YY, Lee SY, Kim JH, Jung BC, et al. Diagnostic accuracy of plasma free metanephrines in a seated position compared with 24-hour urinary metanephrines in the investigation of pheochromocytoma. Endocr J. 2015;62:243–50.CrossRefPubMed
6.
Bayley JP, Oldenburg RA, Nuk J, Hoekstra AS, van der Meer CA, Korpershoek E, et al. Paraganglioma and pheochromocytoma upon maternal transmission of sdhd mutations. BMC Med Genet. 2014;15:111.CrossRefPubMedPubMedCentral
7.
Tschuor C, Sadri H, Clavien PA. Pheochromocytoma crisis. Clinical Case Rep. 2014;2:14.CrossRef
8.
Oshmyansky AR, Mahammedi A, Dackiw A, Ball DW, Schulick RD, Zeiger MA, et al. Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr. 2013;37:820–3.CrossRefPubMed
9.
Balakrishnan G, Ravikumar R, Rao S, Balakrishnan KR. Tetralogy of fallot with pheochromocytoma: an unusual therapeutic challenge. Asian Cardiovasc Thorac Ann. 2013;21:464–6.CrossRefPubMed
10.
Rizak J, Tan H, Zhu H, Wang JF: Chronic treatment with the mood stabilizing drug lithium up-regulates nuclear factor e2-related factor 2 in rat pheochromocytoma pc12 cells in vitro. Neuroscience 2014;256:223–229.
11.
Fudim M, Ely EW, Laffer CL, Elijovich F. Diagnosis of pheochromocytoma on physical examination. Eur Heart J. 2014;35:1705.CrossRefPubMed
12.
Kaku Y, Saito S, Saito H, Yamazaki K. On-pump beating resection of cardiac pheochromocytoma. Asian Cardiovasc Thorac Ann. 2014;22:89–91.CrossRefPubMed
13.
Haddad S, Al-Raiy B, Madkhali A, Al-Qahtani S, Al-Sultan M, Arabi Y. Cardiorespiratory crisis at the end of pregnancy: a case of pheochromocytoma. Middle East J Anaesthesiol. 2013;22:195–202.PubMed
14.
Li W, Yang B, Che JP, Yan Y, Liu M, Li QY, et al. Diagnosis and treatment of extra-adrenal pheochromocytoma of urinary bladder: case report and literature review. Int J Clin Exp Med. 2013;6:832–9.PubMedPubMedCentral
15.
Bausch B, Wellner U, Bausch D, Schiavi F, Barontini M, Sanso G, et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer. 2014;21:17–25.CrossRefPubMed
16.
Baskok FA, Senturk B, Ozeke O, Aras D. Recurrence of cardiomyopathy by recurrent pheochromocytoma. Int J Cardiol. 2013;169:e31–2.CrossRefPubMed
17.
Mohammed AA, El-Shentenawy AM, Sherisher MA, El-Khatib HM. Target therapy in metastatic pheochromocytoma: current perspectives and controversies. Oncol Rev. 2014;8:249.CrossRefPubMedPubMedCentral
18.
Barski D. Management and follow up of extra-adrenal phaeochromocytoma. Central Eur J Urology. 2014;67:156–61.
19.
Jochmanova I, Zelinka T, Widimsky Jr J, Pacak K. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors. Physiol Res. 2014;63 Suppl 2:S251–62.PubMed
20.
Li J, Yang CH. Improvement of preoperative management in patients with adrenal pheochromocytoma. Int J Clinical Exp Med. 2014;7:5541–6.
21.
Lambelin M, Meuris B, Bogaert J, Eggermont N, Sinnaeve PR. Pheochromocytoma as an incidentaloma in severe symptomatic calcified constrictive pericarditis. Acta Cardiol. 2014;69:566–7.PubMed
22.
Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013;98:E1813–9.CrossRefPubMed
23.
Rijken JA, Niemeijer ND, Corssmit EP, Jonker MA, Leemans CR, Menko FH, Hensen EF: Low penetrance of paraganglioma and pheochromocytoma in an extended kindred with a germline sdhb exon 3 deletion. Clinical Genet 2015. doi:10.​1111/​cge.​12591.
24.
Yu X, Li Z. The role of microRNAs expression in laryngeal cancer. Oncotarget 2015;6(27):23297–305.
25.
Li Z, Yu X, Shen J, Law PT, Chan MT, Wu WK. MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget. 2015;6(16):13914–12.CrossRefPubMedPubMedCentral
26.
Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48(3):278–83.CrossRefPubMed
27.
Yu X, Li Z, Liu J. Mirnas in primary cutaneous lymphomas. Cell proliferation 2015; 48:271–7.
28.
Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46:436–46.CrossRefPubMed
29.
Li M, Yu M, Liu C, Zhu H, He X, Peng S, et al. Mir-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif. 2013;46:223–31.CrossRefPubMed
30.
31.
Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48:1–6.CrossRefPubMed
32.
Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.PubMed
33.
Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS One. 2013;8, e83080.CrossRefPubMedPubMedCentral
34.
Li J, You T, Jing J. Mir-125b inhibits cell biological progression of Ewing’s sarcoma by suppressing the PI3k/Akt signalling pathway. Cell Prolif. 2014;47:152–60.CrossRefPubMed
35.
Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277–86.CrossRefPubMed
36.
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.CrossRefPubMed
37.
Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, Feng F. By downregulating tiam1 expression, microrna-329 suppresses gastric cancer invasion and growth. Oncotarget 2015;6:17559–69.
38.
Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 2012;45:32–8.CrossRefPubMed
39.
Fu LL, Yang Y, Xu HL, Cheng Y, Wen X, Ouyang L, et al. Identification of novel caspase/autophagy-related gene switch to cell fate decisions in breast cancers. Cell Prolif. 2013;46:67–75.CrossRefPubMed
40.
Hohjoh H, Fukushima T. Marked change in microRNA expression during neuronal differentiation of human teratocarcinoma NTera2D1 and mouse embryonal carcinoma P19 cells. Biochem Biophys Res Commun. 2007;362:360–7.CrossRefPubMed
41.
Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer. 2010;17:835–46.CrossRefPubMed
42.
Tombol Z, Eder K, Kovacs A, Szabo PM, Kulka J, Liko I, et al. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol. 2010;23:1583–95.CrossRefPubMed
43.
Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer. 2012;19:157–66.CrossRefPubMedPubMedCentral
44.
Hamada N, Fujita Y, Kojima T, Kitamoto A, Akao Y, Nozawa Y, et al. MicroRNA expression profiling of NGF-treated pc12 cells revealed a critical role for miR-221 in neuronal differentiation. Neurochem Int. 2012;60:743–50.CrossRefPubMed
45.
de Cubas AA, Leandro-Garcia LJ, Schiavi F, Mancikova V, Comino-Mendez I, Inglada-Perez L, et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer. 2013;20:477–93.CrossRefPubMed
46.
Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6044.CrossRefPubMedPubMedCentral
47.
Ding L, Zhao L, Chen W, Liu T, Li Z, Li X. Mir-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell. Int J Clinical Exp Med. 2015;8:2299–307.
48.
McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108:1133–42.CrossRefPubMedPubMedCentral
49.
Osugi J, Kimura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, et al. Prognostic impact of hypoxia-inducible miRNA-210 in patients with lung adenocarcinoma. J Oncol. 2015;2015:316745.CrossRefPubMedPubMedCentral
50.
Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, et al. Hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116:2148–58.PubMed
51.
Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015;112(Suppl):1241–6.CrossRefPubMedPubMedCentral
52.
Tsang VH, Dwight T, Benn DE, Meyer-Rochow GY, Gill AJ, Sywak M, et al. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocr Relat Cancer. 2014;21:415–26.CrossRefPubMed
53.
Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guangjian L, Yujie L, Yunchao H: Microrna-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting myb. Cancer letters 2014;347:65–74.
54.
Zhou Y, Jiang H, Gu J, Tang Y, Shen N, Jin Y. MicroRNA-195 targets ADP-ribosylation factor-like protein 2 to induce apoptosis in human embryonic stem cell-derived neural progenitor cells. Cell Death Dis. 2013;4, e695.CrossRefPubMedPubMedCentral
55.
Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 2012;14:278–87.CrossRefPubMedPubMedCentral
56.
Yang X, Yu J, Yin J, Xiang Q, Tang H, Lei X. Mir-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 2012;67:645–51.PubMed
57.
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of mir-195 and mir-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17:1722–30.CrossRefPubMed
58.
Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518:351–9.CrossRefPubMed
59.
Wang L, Qian L, Li X, Yan J. MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. Mol Med Rep. 2014;10:473–8.PubMed
60.
61.
Guo H, Li W, Zheng T, Liu Z. Mir-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol. 2014;35:8861–6.CrossRefPubMed
62.
You XY, Huang JH, Liu B, Liu SJ, Zhong Y, Liu SM. HMGA1 is a new target of mir-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochem Biokhimiia. 2014;79:538–44.CrossRef
63.
Wang X, Wang Y, Lan H, Li J. MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R. Tumour Biol. 2014;35:8765–70.CrossRefPubMed
64.
Jain M, Zhang L, Boufraqech M, Liu-Chittenden Y, Bussey K, Demeure MJ, et al. ZNF367 inhibits cancer progression and is targeted by miR-195. PLoS One. 2014;9, e101423.CrossRefPubMedPubMedCentral
65.
Liu JJ, Lin XJ, Yang XJ, Zhou L, He S, Zhuang SM, et al. A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res. 2014;42:12041–51.CrossRefPubMedPubMedCentral
66.
Lin X, Guan H, Li H, Liu L, Liu J, Wei G, et al. MiR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Re. 2014;2:122–6.
67.
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, et al. MicroRNA-101 targets EZH, 2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014;5:6049–62.CrossRefPubMedPubMedCentral
68.
Wang L, Li L, Guo R, Li X, Lu Y, Guan X, et al. Mir-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. Cell Physiol Biochem. 2014;34:413–22.CrossRefPubMed
69.
Zhang K, Zhang Y, Ren K, Zhao G, Yan K, Ma B. Microrna-101 inhibits the metastasis of osteosarcoma cells by downregulation of ezh2 expression. Oncol Rep 2014;32:2143–9.
70.
Zhang J, Han C, Zhu H, Song K, Wu T. MiR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol. 2013;182:1629–39.CrossRefPubMedPubMedCentral
71.
Chen S, Wang H, Ng WL, Curran WJ, Wang Y. Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys. 2011;81:1524–9.CrossRefPubMed
72.
Sun Q, Liu T, Zhang T, Du S, Xie GX, Lin X, et al. MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1. Mol Med Rep. 2015;11:3330–6.PubMedPubMedCentral
73.
Yin J, Wang M, Jin C, Qi Q. Mir-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett. 2014;7:461–5.PubMed
74.
Zong L, Meng L, Shi R. Role of miR-101 in pheochromocytoma patients with SDHD mutation. Int J Clin Exp Pathol. 2015;8:1545–54.PubMedPubMedCentral
Metadata
Title
The role of miRNAs in the pheochromocytomas
Authors
Zheng Li
Xin Yu
Jianxiong Shen
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4199-z

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue

Original Article

Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas

Original Article

Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics

Original Article

Function analysis of rs9589207 polymorphism in miR-92a in gastric cancer

Original Article

Esculetin, a natural coumarin compound, evokes Ca2+ movement and activation of Ca2+-associated mitochondrial apoptotic pathways that involved cell cycle arrest in ZR-75-1 human breast cancer cells

Original Article

Application of multispectral imaging in quantitative immunohistochemistry study of breast cancer: a comparative study

Original Article

Interleukin 10 gene −1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits